Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US?

Gregory F Guzauskas, MSPH, PhD, Anthony Masaquel, MPH, PhD, Per-Olof Thuresson, MSc, Jia Li, PhD, Carolina M Reyes, PhD, David Veenstra, PharmD, PhD

Blood (2017) 130 (Supplement 1): 5603.

https://doi.org/10.1182/blood.V130.Suppl_1.5603.5603

Published: 2017

Journal Articles

How Time Spent on Rituximab Infusion Impacts Patient Satisfaction, Stress, Employment, and Caregiver Burden

Maxine D Fisher, PhD, Christopher Wallick, PharmD, Paul J Miller, PhD, Mark S Walker, PhD, Stephen Lash, PharmD, Keith L Dawson, DNP, Carolina M Reyes, PhD

Blood (2017) 130 (Supplement 1): 5666.

https://doi.org/10.1182/blood.V130.Suppl_1.5666.5666

Published: 2017

Journal Articles

Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

Jeffrey P. Sharman, MD, Habte Yimer, MD, Michael Boxer, MD, Nicholas Di Bella, Sunil Babu, Jia Li, PhD, Yong Mun, Peter Trask, Anthony Masaquel, MPH, PhD, Carolina M Reyes, PhD, Alexey Danilov, MD PhD

Blood (2017) 130 (Supplement 1): 683.

https://doi.org/10.1182/blood.V130.Suppl_1.683.683

Published: 2017

Journal Articles

Maintenance Rituximab after First Line Treatment in Veterans with Follicular Lymphoma Is Associated with Prolonged Overall Survival

Ahmad S. Halwani, MD, Kelli Rasmussen, MS, Vikas Patil, MS, Zach Burningham, PhD, Clarke Low, MD, Carolina M Reyes, PhD, Anthony Masaquel, MPH, PhD, Kevin Henderson, PharmD, MBA, Elisha Delong-Sieg, PharmD, Brian C Sauer, PhD

Blood (2017) 130 (Supplement 1): 1489.

https://doi.org/10.1182/blood.V130.Suppl_1.1489.1489

Published: 2017

Journal Articles

Health-Related Quality of Life of Patients Diagnosed with Indolent Lymphoma.

Susan D. Mathias, MPH, Tricia A. Cimms, BS, Hilary H. Colwell, MPH, Carolina M. Reyes, PhD, Deborah P. Lubeck, PhD

Blood (2006) 108 (11): 5524.

https://doi.org/10.1182/blood.V108.11.5524.5524

Published: 2006

NARROW

Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US?

How Time Spent on Rituximab Infusion Impacts Patient Satisfaction, Stress, Employment, and Caregiver Burden

Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

Maintenance Rituximab after First Line Treatment in Veterans with Follicular Lymphoma Is Associated with Prolonged Overall Survival

Health-Related Quality of Life of Patients Diagnosed with Indolent Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US?

How Time Spent on Rituximab Infusion Impacts Patient Satisfaction, Stress, Employment, and Caregiver Burden

Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

Maintenance Rituximab after First Line Treatment in Veterans with Follicular Lymphoma Is Associated with Prolonged Overall Survival

Health-Related Quality of Life of Patients Diagnosed with Indolent Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only